In the pharmaceutical and life sciences sectors, we are beginning to see how novel technologies, such as Machine-to-Machine (M2M) communication, Artificial Intelligence (AI), and the Industrial Internet of Things (IIoT) can play a role in fostering innovation, improving product authentication, and transforming traditional operational models.
Maintaining consistent quality assurance across complex manufacturing processes is a growing struggle, and addressing these challenges within the pharma and life sciences sectors is not optional; it is imperative for safeguarding public health. To navigate these issues, forward-thinking organizations will move toward the adoption of emerging digital platforms designed to enhance security, traceability, and quality assurance.
These digital platforms leverage new software and hardware technologies, enabling industry organizations to immutably link a physical object with its digital twin in a secure ecosystem that minimizes risks, ensures product authenticity, and maintains unwavering quality standards. The eventual transition to these platforms and their more reliable digital frameworks brings numerous benefits – from enhanced security to regulatory compliance to operational efficiency. Cyber-physical trust is poised to change the industry’s future.
An Opportunity to Enhance Operational Excellence
Manufacturers in the pharmaceutical and life sciences industry today face critical challenges that threaten their ability to deliver safe, effective, and reliable therapies to patients worldwide. Security breaches, supply chain vulnerabilities, counterfeit threats, and quality assurance challenges are not just operational risks, they directly impact patient safety and regulatory compliance.
Counterfeit medicines are on the rise, according to data from the Pharmaceutical Security Institute.1 Almost 6,000 pharmaceutical crime incidents were recorded in 2021, up 38 percent from the year before and the peak figure since their records began 20 years ago.1
The pharmaceutical industry operates under a web of stringent regulations, and compliance is becoming increasingly complex. The FDA’s cybersecurity guidelines, emphasize the need for robust frameworks to protect digital assets and ensure patient safety.2 Regulatory mandates like the FDA’s Drug Supply Chain Security Act (DSCSA) require pharmaceutical companies to implement systems for end-to-end product traceability.3
This crucial global mandate aims to facilitate drug traceability and help ensure patient safety. If any link along the supply chain is not able to receive and transmit the tracing information electronically, the drug cannot move to its next step.
Regulatory compliance should be seen not as a hurdle but as an opportunity to enhance operational excellence. By fostering collaboration and embracing digital innovation that enables cyber-physical trust, the pharmaceutical and life sciences industry can navigate these complexities, ensuring it remains a cornerstone of global health and well-being.
Cyber-physical trust helps organizations meet compliance requirements by providing a reliable and auditable trail of product authenticity and quality, and by leveraging advanced Web 3.0 technology and the creation of digital twins we can ensure that product data is secure and tamper proof, reducing the risk of counterfeit goods and improving overall product integrity.
Harnessing Digital Technology to Support Supply Chain Resilience
Innovations such as AI, blockchain, and IIoT devices can not only address operational challenges but also deliver measurable outcomes that improve operational efficiency and support supply chain resilience.
As the industry becomes increasingly data-driven, protecting sensitive information, ranging from patient records to proprietary research, is paramount. Blockchain technology offers a secure record-keeping system that can help to ensure data integrity and traceability.
Combined with encryption and advanced authentication methods, it provides robust protection against cyberattacks and unauthorized access.
Blockchain can address issues, such as verifying the origin of raw materials and finished products, and provides immutable records of every step in the supply chain, ensuring transparency and authenticity from manufacturing to distribution.
Variability in raw materials, processes, and oversight can lead to deviations that compromise product efficacy and safety. Advanced process control systems and IoT-enabled monitoring devices are essential for ensuring standardization and real-time adjustments to manufacturing processes.
Moving to More Reliable and Efficient Digital Frameworks
To comply with ever-emerging regulatory mandates, manufacturers must create cybersecurity frameworks that are embedded into every layer of their supply chain. To do this, they need to move from traditional manual processes to more reliable digital frameworks; cyber-physical trust enables this digitalization.
A cyber-physical trust platform is designed to ensure secure, reliable, and trustworthy interaction between the digital and physical components of a networked environment. These platforms are particularly relevant in industries like pharmaceuticals, manufacturing, and healthcare, where both digital systems (e.g., databases, software) and physical systems (e.g., machinery, sensors, supply chain components) must work seamlessly together while maintaining elevated levels of security and transparency.
Cyber-physical trust platforms excel in ensuring traceability by linking physical products to digital records through IoT and blockchain. They also provide real-time audit trails that meet regulatory requirements for transparency and accountability, and they minimize counterfeit risks by verifying the origin and authenticity of raw materials and finished goods.
Digital twins – virtual representations of physical systems or processes – can improve traceability and quality assurances in industries like pharmaceuticals and life sciences. By integrating real-time data from physical assets with advanced analytics and simulation capabilities, digital twins offer several ways to enhance traceability and quality control.
Adopt and Integrate – Keeping Up with the Changing Landscape
Cyber-physical trust platforms are likely to become integral to the pharmaceutical product manufacturing sector over the nextfivee years. The convergence of increasing regulatory demands, technological advancements, and the need for operational efficiency will drive their adoption.
As more companies adopt cyber-physical trust platforms, we could see industry-wide collaboration also increase. Shared platforms and standardized protocols will enable interoperability across supply chains and manufacturing networks, as well as streamlined regulatory submissions, reducing the time to market for new products.
We can hope to see cyber-physical trust platforms evolve from being a strategic advantage to a fundamental requirement in pharmaceutical manufacturing. Their ability to enhance security, ensure regulatory compliance, optimize operations, and improve supply chain transparency could position them as cornerstone technologies in the sector’s digital transformation.
Organizations that adopt and integrate these platforms early will not only safeguard their operations but also gain a competitive edge in a rapidly changing landscape.
References
- Pharmaceutical Security Institute (PSI). Incident trends. Available at: https://www.psi-inc. oOrgincident-trends. Accessed February 25, 2025.
- U.S. Food and Drug Administration (FDA). Cybersecurity. Available at: https://www.fda. Gov/about-fda/cybersecurity. Accessed February 25, 2025.
- U.S. Food and Drug Administration (FDA). Drug Supply Chain Security Act (DSCSA). Available at: https://www.fda.gov/drug-supply-chain-security-act-dscsa. Accessed February 25, 2025.
Author Details
James Kugler- CEO of EMD Digital and Chief Digital Officer, Merck KGaA, Darmstadt, Germany
James Kugler is the CEO of EMD Digital and Chief Digital Officer of Merck KGaA, Darmstadt, Germany (www.emdgroup. com), EVP of Athinia (www.athinia.com), and a member of the board of directors of Syntropy (www.syntropy.com).
Under the EMD Digital umbrella, James is responsible for spearheading new digital business ventures that advance the company’s commitment to materials quality into the digital era. James continues to encourage the internal incubation of innovative businesses, particularly by representing the digital perspective on Merck KGaA, Darmstadt, Germany’s Innovation & Technology Executive Committee (ITEC).
James and his team launched in January 2025 a beta version of M-TrustTM, a secure cyber-physical trust platform, created to help solve the growing issues of product safety, traceability, and counterfeiting.
James began his journey in science early, conducting research at Harvard and MIT while still in high school. He joined Sigma-Aldrich in 2008 as an intern while finishing his degree in Biomedical Engineering at Washington University in St. Louis and went on to lead the growth of Sigma-Aldrich. com to over $1 billion in annual revenue before the company’s acquisition by Merck KGaA, Darmstadt, Germany in 2014.
Recognized for his experience in transforming enterprises and building ecosystems in complex, highly regulated industries, James is deeply committed to advancing scientific quality and accelerating breakthrough technologies through digital innovation, and he is passionate about the importance of data quality and human expertise in the age of generative AI.
Publication Details
This article appeared in American Pharmaceutical Review:Vol. 28, No. 2March 2025Pages: 52-54
Subscribe to our e-Newsletters.
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!